180 related articles for article (PubMed ID: 22414081)
1. Novel patented SRC kinase inhibitor.
Lu XL; Liu XY; Cao X; Jiao BH
Curr Med Chem; 2012; 19(12):1821-9. PubMed ID: 22414081
[TBL] [Abstract][Full Text] [Related]
2. Recent progress of SRC family kinase inhibitors as anticancer agents.
Cao X; You QD; Li ZY; Wang XJ; Lu XY; Liu XR; Xu D; Liu B
Mini Rev Med Chem; 2008 Sep; 8(10):1053-63. PubMed ID: 18782057
[TBL] [Abstract][Full Text] [Related]
3. Recent progress of Src SH2 and SH3 inhibitors as anticancer agents.
Lu XL; Cao X; Liu XY; Jiao BH
Curr Med Chem; 2010; 17(12):1117-24. PubMed ID: 20158477
[TBL] [Abstract][Full Text] [Related]
4. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
6. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
8. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.
Kim MP; Park SI; Kopetz S; Gallick GE
Cell Tissue Res; 2009 Jan; 335(1):249-59. PubMed ID: 18815812
[TBL] [Abstract][Full Text] [Related]
9. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
10. Synthetic SRC-kinase domain inhibitors and their structural requirements.
Schenone S; Manetti F; Botta M
Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
[TBL] [Abstract][Full Text] [Related]
11. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
12. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
13. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
14. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
[TBL] [Abstract][Full Text] [Related]
15. Src kinase inhibitors: promising cancer therapeutics?
Creedon H; Brunton VG
Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of Src expression and activity in human neoplasia.
Chatzizacharias NA; Kouraklis GP; Giaginis CT; Theocharis SE
Histol Histopathol; 2012 Jun; 27(6):677-92. PubMed ID: 22473690
[TBL] [Abstract][Full Text] [Related]
17. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
18. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Ahluwalia MS; de Groot J; Liu WM; Gladson CL
Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
[TBL] [Abstract][Full Text] [Related]
19. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
20. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.
Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M
ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
